

June 24, 2008

Immediate Release

Meiji Seika Kaisha Ltd.  
Astellas Pharma Inc.  
Solvay Seiyaku K. K.

New strength added to fluvoxamine maleate, 75mg tablets launched
--

Meiji Seika Kaisha Ltd. (Head Office: Chuo-ku Tokyo, President: Naotada Sato, hereinafter referred to as Meiji), Astellas Pharma Inc. (Head Office: Chuo-ku Tokyo, President: Masafumi Nogimori, hereinafter referred to as Astellas) and Solvay Seiyaku K. K. (Head Office: Kita-ku Tokyo, President: Koji Ohiwa, hereinafter referred to as Solvay Seiyaku ) today announce the launch of 75mg tablets of fluvoxamine maleate which was originally launched in 1999 as the first SSRI (Selective Serotonin Reuptake Inhibitor) in Japan with the brand names of “DEPROMEL<sup>®</sup> 75” (manufactured and distributed by Meiji) and “Luvox<sup>®</sup> 75” (distributed by Astellas, manufactured and distributed by Solvay Seiyaku) in addition to currently available 25mg and 50mg tablets from June 25<sup>th</sup>.

The new strength, 75mg tablets, will be used for the approved dose of 150mg/day for the following indications: depression/ depressive state, obsessive compulsive disorder and social anxiety disorder. The companies expect this new strength to contribute to improvement of patients' regimen compliance and providing a new option of antidepressant treatment for physicians.

#####

Contacts for inquiries or additional information:

Meiji Seika Kaisha Ltd. Customer Communication Dept. IR/ PR Room TEL: 03-3273-3355 FAX : 03-3281-7046 <a href="http://www.meiji.co.jp">http://www.meiji.co.jp</a>	Astellas Pharma Inc. Corporate Communications  TEL: 03-3244-3201 FAX : 03-5201-7473 <a href="http://www.astellas.com/jp">http://www.astellas.com/jp</a>	Solvay Seiyaku K. K. Medical Marketing Div. Tsuji, Imai TEL: 03-5814-0838 FAX: 03-5814-0860 <a href="http://www.solvay.jp">http://www.solvay.jp</a>
--	--	--